ArticleNPJ vaccines2024
Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.
Open access · goldAbstract read
In one paragraph
Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants.Human vaccines & immunotherapeutics · 2026Trial
- Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.Cell reports · 2025Trial
- Validation of a Mucosal IgA Assay for SARS-CoV-2.Microorganisms · 2026Article
- Spatial transcriptomic mapping of early immune responses to an adjuvanted recombinant hemagglutinin vaccine.Frontiers in immunology · 2026Article
- Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms.NPJ vaccines · 2025Review
- Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment.Human vaccines & immunotherapeutics · 2025Article
- Immunogenicity and innate immunity to high-dose and repeated vaccination of modified mRNA versus unmodified mRNA.Molecular therapy. Nucleic acids · 2025Article
- Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-MNature communications · 2025Article
- Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication.Nature communications · 2025Article
- Biochemical and hematological reference intervals in rhesus and cynomolgus macaques and implications for vaccine and drug development.Lab animal · 2025Article
- Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity.NPJ vaccines · 2025Article
- The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in nonhuman primates.The Journal of clinical investigation · 2025Article
- Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.Vaccines · 2025Review
- Destabilising Effect of Class B CpG Adjuvants on Different Proteins and Vaccine Candidates.Vaccines · 2025Article
- Modulation of antigen delivery and lymph node activation in nonhuman primates by saponin adjuvant saponin/monophosphoryl lipid A nanoparticle.PNAS nexus · 2024Article
- Enhanced RBD-Specific Antibody Responses and SARS-CoV-2-Relevant T-Cell Activity in Healthcare Workers Following Booster Vaccination.Current issues in molecular biology · 2024Article
- Modulation of antigen delivery and lymph node activation in non-human primates by saponin adjuvant SMNP.bioRxiv : the preprint server for biology · 2024Article
- Intranasal Delivery ofVaccines · 2024Article
- An experimental chimeric hepatitis E virus vaccine elicits both local and systemic immune responses.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 3 countries.
Klara LenartDepartment of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-4984-2618
Rodrigo Arcoverde Cerveira *Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-1145-2534
Fredrika Hellgren *Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.
Sebastian OlsDepartment of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-9784-7176
Daniel J ShewardDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-0227-5636
Changil KimDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-4977-4384
Alberto CagigiDepartment of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden.
Matthew GagneVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5526-6162
Brandon DavisRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Daritza GermosenRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Vicky RoyRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5064-1098
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Hélène LetscherUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
Jérôme Van WassenhoveUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.ORCID http://orcid.org/0000-0001-7298-465X
Wesley GrosUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
Anne-Sophie GallouëtUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
Roger Le GrandUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.ORCID http://orcid.org/0000-0002-4928-4484
Harry KleanthousBill & Melinda Gates Foundation, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-7115-235X
Mimi Guebre-XabierNovavax Inc, Gaithersburg, MD, USA.
Ben MurrellDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-0393-4445
Nita PatelNovavax Inc, Gaithersburg, MD, USA.
Gregory GlennNovavax Inc, Gaithersburg, MD, USA.
Gale SmithNovavax Inc, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0002-6482-6026
Karin LoréDepartment of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden. karin.lore@ki.se.ORCID http://orcid.org/0000-0001-7679-9494
Karolinska University Hospital · SEInserm · FRNovavax (United States) · USRagon Institute of MGH, MIT and Harvard · USKarolinska Institutet · SEGates Foundation · USNational Institutes of Health · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune responses to Novavax's licensed NVX-CoV2373 nanoparticle Spike protein vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus macaques that immunization with Matrix-M
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.